A new trading day began on Monday, with Trevi Therapeutics Inc (NASDAQ: TRVI) stock price up 7.11% from the previous day of trading, before settling in for the closing price of $3.94. TRVI’s price has ranged from $1.35 to $4.68 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -67.11%. With a float of $58.06 million, this company’s outstanding shares have now reached $75.45 million.
Let’s determine the extent of company efficiency that accounts for 25 employees. In terms of profitability, gross margin is 38.64%, operating margin of -27394.89%, and the pretax margin is -25196.59%.
Trevi Therapeutics Inc (TRVI) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Trevi Therapeutics Inc is 35.03%, while institutional ownership is 35.37%. The most recent insider transaction that took place on Sep 06 ’24, was worth 12,784. In this transaction President & CEO of this company sold 4,219 shares at a rate of $3.03, taking the stock ownership to the 213,313 shares. Before that another transaction happened on Sep 09 ’24, when Company’s President & CEO sold 1,840 for $3.04, making the entire transaction worth $5,587. This insider now owns 213,313 shares in total.
Trevi Therapeutics Inc (TRVI) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -67.11% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -22.64% during the next five years compared to 27.24% growth over the previous five years of trading.
Trevi Therapeutics Inc (NASDAQ: TRVI) Trading Performance Indicators
Here are Trevi Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 7.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.44, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.49 in one year’s time.
Technical Analysis of Trevi Therapeutics Inc (TRVI)
Looking closely at Trevi Therapeutics Inc (NASDAQ: TRVI), its last 5-days average volume was 0.5 million, which is a drop from its year-to-date volume of 0.52 million. As of the previous 9 days, the stock’s Stochastic %D was 80.26%. Additionally, its Average True Range was 0.29.
During the past 100 days, Trevi Therapeutics Inc’s (TRVI) raw stochastic average was set at 80.17%, which indicates a significant decrease from 90.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 55.10% in the past 14 days, which was lower than the 87.43% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.63, while its 200-day Moving Average is $3.09. However, in the short run, Trevi Therapeutics Inc’s stock first resistance to watch stands at $4.39. Second resistance stands at $4.55. The third major resistance level sits at $4.81. If the price goes on to break the first support level at $3.96, it is likely to go to the next support level at $3.70. Should the price break the second support level, the third support level stands at $3.54.
Trevi Therapeutics Inc (NASDAQ: TRVI) Key Stats
With a market capitalization of 377.12 million, the company has a total of 76,866K Shares Outstanding. Currently, annual sales are 0 K while annual income is -29,070 K. The company’s previous quarter sales were 0 K while its latest quarter income was -13,240 K.
